Author/Authors :
Kumar, Meet Nil Ratan Sircar Medical College and Hospital - Department of Hematology, India , Panigrahi, Ashutosh Nil Ratan Sircar Medical College and Hospital - Department of Hematology, India , Dolai, Tuphan K. Nil Ratan Sircar Medical College and Hospital - Department of Hematology, India , De, Rajib Nil Ratan Sircar Medical College and Hospital - Department of Hematology, India , Mandal, Prakas K. Nil Ratan Sircar Medical College and Hospital - Department of Hematology, India , Chakrabarti, Prantar Nil Ratan Sircar Medical College and Hospital - Department of Hematology, India
Abstract :
Background Myeloma management has evolved over the years with logarithmic expansion of available treatment options. The treatment algorithms are also changing because of the better responses obtained with newer agents. Bortezomib, thalidomide and dexamathasone (also known as VTD) is one such therapy that has shown improved long term outcomes. Materials and methods We conducted a single-center, retrospective analysis of all myeloma patients treated with VTD chemotherapy. Results An overall response achieved was 85.7% with 40% CR. Conclusion We conclude VTD is an effective chemotherapy regimen in newly-diagnosed myeloma patients.
